StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer’s (PFE) $6.7B Arena Acquisition is Priced Reasonably, May Offer Additional Upside, Pfizer Making Good Use of Cash – Analyst
December 13, 2021 9:30 AM
Earlier today, Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that the companies have entered into a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Mergers and Acquisitions
Trader Talk
Next Articles
Pfizer (PFE) Announces FDA Approval of XELJANZ for the Treatment of Active Ankylosing Spondylitis
December 14, 2021 4:08 PM
Pre-Open Stock Movers 12/13: (ARNA) (FHTX) (HOG) Higher; (NISN) (TXMD) (AMPE) Lower (more...)
December 13, 2021 9:21 AM
Low Valuations to Drive Pharma M&A in 2022 - Analyst
December 13, 2021 8:50 AM
Pfizer (PFE) to Buy Arena Pharmaceuticals (ARNA) in a $6.7 Billion Deal, Pays a 100% Premium; Seen as the First of Many Acquisitions
December 13, 2021 6:41 AM
Pfizer bets on Arena's promising bowel disease treatment in $6.7 billion deal
December 13, 2021 6:33 AM
Pfizer (PFE) to Acquire Arena Pharmaceuticals (ARNA) for $100 Per Share, $6.7 Billion Deal
December 13, 2021 6:11 AM
Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
December 13, 2021 5:04 AM
UPDATE: UBS Upgrades Pfizer (PFE) to Buy
December 13, 2021 3:53 AM
Pfizer (PFE) Raises Quarterly Dividend 2.6% to $0.40; 3% Yield
December 10, 2021 12:01 PM
